1. Introduction {#s0005}
===============

The relationship between the cellular response to oxygen and the detoxification of reactive oxygen species (ROS) is an ancient one [@bib1]. Oxygen is used for the conversion of sugar into ATP via mitochondrial oxidative phosphorylation, creating endogenous ROS as a byproduct. ROS have the potential to react with and damage all classes of macromolecules, so they are often viewed as cytotoxic. Consistent with this, decades of toxicity studies have reliably shown that damaging levels of ROS are generated when cells are exposed to a range of environmental xenobiotics. However, despite their cytotoxic potential, ROS are also required for proper cell signaling and development. Many properties of ROS make them ideal signaling molecules, including their potential for rapid modification of proteins and close ties to cellular metabolism [@bib2], [@bib3]. In fact, many proteins that regulate angiogenesis, cell cycle progression, stem cell self-renewal, and differentiation are activated upon being oxidized by ROS [@bib4], [@bib5], [@bib6], [@bib7]. Thus, the role of cellular ROS is somewhat paradoxical: ROS can cause damage with potentially dire consequences, yet ROS are required as signaling molecules for normal development. Fortunately, cells have evolved many antioxidant mechanisms that can directly combat the harmful effects of ROS, while keeping ROS levels tightly balanced in order to prevent disruption of redox homeostasis.

Much of the response to ROS is regulated at the transcriptional level, and vertebrates have multiple redox-responsive transcription factors (TFs). This includes TFs commonly viewed as stress-responsive like NRF2 (encoded by the gene *NFE2L2*), p53 (encoded by the gene *TP53*), HIF1α (encoded by the gene *HIF1A*), as well as immunomodulatory TFs such as NF-κB, STAT, and the AP-1 complex (Fos/Jun), and more [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15]. The range of processes regulated by these TFs is broad: factors like NRF2 and p53 regulate extensive gene networks responsible for mitigating ROS-induced damage, whereas HIF1α regulates the adaptive response to hypoxia [@bib9], [@bib16], [@bib17]. Considering the number of redox-responsive TFs encoded within metazoan genomes, there is significant potential for crosstalk between these TF regulatory networks during the fine-tuning of gene expression changes in response to changing levels of oxygen or ROS.

NRF2, a key regulator of the transcriptional response to oxidative stress, and HIF1α, a key regulator of the transcriptional response to hypoxic stress, represent an interesting pair of TFs with underappreciated potential for functional connectivity. Both TFs regulate oxygen-associated processes but, considering the environments to which they are most responsive, are often viewed to be on opposite ends of spectrum. Nevertheless, the activities of both NRF2 and HIF1α are regulated by ROS. NRF2 activity is largely regulated by KEAP1, an inhibitory protein that binds cytoplasmic NRF2 and targets it for proteosomal degradation, and KEAP1 contains over two dozen cysteine residues that can be modified by ROS [@bib18]. ROS modification of KEAP1\'s cysteine residues decreases its ability to target NRF2 for ubiquitination so, as a consequence, NRF2 activity is increased by ROS. HIF1α is regulated via a similar mechanism. In general, HIF1α activity is low during normoxia -- this is regulated by prolyl hydroxylase (PHD) proteins that hydroxylate HIF1α and target it for proteasomal degradation [@bib19], [@bib20]. However, hypoxia triggers a paradoxical increase in ROS generation at the mitochondria, these hypoxia-induced ROS inhibit PHD activity and, therefore, increase HIF1α stability and activity [@bib21], [@bib22], [@bib23], [@bib24], [@bib25]. Thus, although they regulate two very different adaptive responses, the stability and activity of both NRF2 and HIF1α are regulated by ROS.

Because ROS can modify the activity of many TF networks, an unbiased genome-wide view of the transcriptional response to ROS has the potential to identify novel connections between redox-responsive TFs. With this in mind, we integrated publicly available transcriptomic data that measured the dynamics of gene expression in response of human hepatoma cells (HepG2) to multiple ROS inducers [@bib26] with TF binding data (genome-wide chromatin immunoprecipitation, or ChIP-seq) from multiple sources [@bib27], [@bib28], [@bib29], [@bib30]. Several unique gene expression clusters were identified, including a prominent gene set induced within hours of ROS exposure that was also enriched for NRF2 ChIP-seq targets. Notably, network analysis revealed *HIF1A*, the gene that encodes HIF1α, as a central member of this gene set. We confirmed these genomic findings in multiple cell lines, we identified a functional NRF2 binding site (i.e., an antioxidant response element, or ARE) approximately 32 kilobases upstream of *HIF1A*, and we found that oncogenic NRF2 mutations are associated with high *HIF1A* expression in multiple cancer types. These findings are consistent with recent work suggesting NRF2 plays a role in *HIF1A* expression [@bib31], [@bib32], and our work lends further support to a model in which NRF2 is a direct regulator of *HIF1A* transcription.

2. Results and discussion {#s0010}
=========================

2.1. A genome-wide view of the transcriptional response to oxidative stress {#s0015}
---------------------------------------------------------------------------

To get a global view of the transcriptional response to ROS we made use of a well-designed, previously published expression profiling dataset [@bib26]. This time course microarray study monitored gene expression in HepG2 cells treated with menadione, *tert*-butyl hydroperoxide, or hydrogen peroxide; we focused on the 0.5, 1, 2, 4, 8, and 24 h time points following exposure to menadione or *tert*-butyl hydroperoxide (TBOOH), as these samples had the most robust ROS-mediated gene expression changes. From these data, we generated a list of differentially expressed genes consisting of any gene that was induced or repressed at least 1.5-fold at any time point post-ROS induction, and used hierarchical clustering to identify gene sets with similar expression patterns ([Fig. 1](#f0005){ref-type="fig"}A). The responses to menadione and TBOOH were generally concordant, although transcriptional changes in response to menadione were apparent at earlier time points and often continued until 24 h post-treatment, whereas the transcriptional response to TBOOH peaked after 8 h. Nevertheless, despite this difference, the gene expression changes associated with these distinct oxidants allowed for identification of genes consistently up- or downregulated by ROS. Several interesting gene expression clusters emerged from this analysis ([Fig. 1](#f0005){ref-type="fig"}A; [Supplementary Table 1](#s0085){ref-type="sec"}). For example, Cluster 1 consists of genes induced within the first 8 h after oxidative stress, whereas Cluster 2 consists of genes that required a full 24 h of menadione treatment before they were robustly induced. Similarly, genes in Clusters 6 and 7 were repressed within the first 8 h after oxidative stress, and genes in Cluster 10 required 24 h of menadione treatment before they were strongly repressed.Fig. 1A cluster of putative NRF2-dependent, ROS-responsive genes includes *HIF1A*. (A) Hierarchical clustering of gene expression changes after exposure of human hepatoma cell line (HepG2) to the ROS inducers menadione or *tert*-butyl hydroperoxide (TBOOH) for 0.5, 1, 2, 4, 8, and 24 h. Data are from Deferme et al. Genes that were induced or repressed at least 1.5-fold in any of these conditions are included; yellow represents induction by ROS, blue represents repression by ROS, and black represents no change. (B) Cluster 1 is enriched for genes involved in signal transduction and cell motility, and enriched for genes called as NRF2 targets based on genome-wide chromatin immunoprecipitation (ChIP-seq) data. P-values (Fisher\'s exact test) are as calculated by Enrichr [@bib30]. Network analysis [@bib38] based on protein-protein interactions highlighted HIF1A (yellow) as central to Cluster 1 (see also [Supplementary Table 2](#s0085){ref-type="sec"}). (C) The same network described in (B), zoomed in to highlight HIF1A.Fig. 1

Considering each expression cluster consists of genes following the same expression pattern, we next asked whether the genes in each cluster were likely to be regulated by the same transcription factors (TFs). We used Enrichr [@bib30], which has compiled hundreds of publicly available ChIP-seq datasets, to scan for TFs that bind near a significant fraction of the genes in each cluster (see Methods) ([Supplementary Table 2](#s0085){ref-type="sec"}). Nine of the fourteen clusters were significantly associated with at least one TF. Cluster 1, for example, is most significantly associated with loci bound by NRF2, one of the established ROS-responsive TFs [@bib33], [@bib34]. NRF2 is also one of the top three TFs associated with Cluster 2, but this cluster is most enriched for RUNX1-bound genes. Interestingly, although RUNX1 has not previously been implicated with gene induction in response to ROS, RNT-1, a nematode ortholog of RUNX1, regulates oxidative stress responsive gene expression in *Caenorhabditis elegans* [@bib35]; this connection may indicate a previously unrecognized redox-responsive role for human RUNX1. Repressed gene sets are associated with TFs like the cell cycle regulator E2F4 (Clusters 6, 10, 14) [@bib36] and hepatocyte specification factor HNF4A (Cluster 10) [@bib37], suggesting that prolonged ROS exposure represses both proliferation and hepatocyte identity regulatory networks. Overall, these clusters of co-expressed genes and their associated TFs represent a valuable platform for identifying potential connections between the regulatory networks that respond to ROS.

2.2. Network analysis highlights *HIF1A* as a ROS-induced gene {#s0020}
--------------------------------------------------------------

We next chose to focus on Cluster 1, which was interesting for multiple reasons. First, of the two largest clusters upregulated by ROS (Clusters 1 and 2), genes in Cluster 1 responded much faster and were generally induced within the first 8 h after oxidant exposure. Second, this cluster was enriched for NRF2 target genes based on overlap with ChIP-seq data, and the cluster contains many expected NRF2 targets, including *HMOX1*, *GCLC*, *GCLM*, *SLC7A11*, *SQSTM1*, *KEAP1*, and *EPHA2*. Combined, these trends suggest this is a rapidly-responding and functionally relevant gene set. However, Cluster 1 consists of 381 genes, so it is made up of more than just canonical antioxidant response genes; this is also evident based on the top gene ontology enrichment categories for this cluster (regulation of cell migration \[GO:0030334\]; regulation of signal transduction \[GO:0009966\]) neither of which are the clearly linked to the antioxidant response ([Fig. 1](#f0005){ref-type="fig"}B). Therefore, we used network analysis [@bib38] to find potentially interesting genes within Cluster 1 ([Fig. 1](#f0005){ref-type="fig"}B--C). Network analysis links genes based on known physical or genetic interactions, and highly linked genes in a network are often functionally important [@bib39], [@bib40]. The five most central members of the Cluster 1 network (based on betweenness centrality) were *SQSTM1*, *UBE2D1*, *CBL*, *TRIM21*, and *HIF1A* ([Supplementary Table 3](#s0085){ref-type="sec"}). SQSTM1 is involved in multiple protein degradation pathways, UBE2D1 is a ubiquitin-conjugating enzyme, and CBL and TRIM21 are both ubiquitin ligases -- although all four are likely to play an important role in the response to ROS, and SQSTM1 is a well-characterized NRF2 target gene, the network centrality of these proteins can be explained by the broad protein-protein interaction spectrum associated with ubiquitin mediated degradation [@bib41], [@bib42], [@bib43], [@bib44]. However, *HIF1A*, which encodes HIF1α, is typically associated with hypoxic stress and, therefore, an unanticipated member of this gene set. Nevertheless, *HIF1A*\'s central presence in Cluster 1 suggests it is subject to ROS-responsive transcriptional regulation, and implies a potential role for NRF2, so we set out to explore *HIF1A* regulation in more detail.

The *HIF1A* expression pattern described above was based on microarray data from HepG2 cells. To verify that *HIF1A* is a ROS-responsive transcript in multiple contexts, we monitored its expression in HepG2 and two breast cancer cell lines, MCF7 and MDA-MB-231, after exposure to menadione or TBOOH. Breast cancer cells, particularly the triple-negative cell line MDA-MB-231, were chosen because high HIF1α expression in these cells is associated with multiple negative characteristics (chemoresistance, pluripotency, etc.) [@bib45], [@bib46]. To ensure we were measuring a response to ROS and avoid measuring gene expression changes associated with cell death, gene expression was monitored after eight hours of exposure, based on menadione or TBOOH concentrations that left at least 80% viable cells after 24 h for each cell line. Indeed, *HIF1A* expression was significantly induced by both menadione and TBOOH in all three cell lines ([Fig. 2](#f0010){ref-type="fig"} and [Supplementary Fig. 1](#s0085){ref-type="sec"}).Fig. 2Menadione treatment increases *HIF1A* mRNA expression in multiple cell types. (A) *HIF1A* expression in HepG2 cells treated for 8 h with vehicle control (ethanol, EtOH) or menadione. Gene expression values were measured by quantitative reverse transcription PCR, and normalized relative to *ACTB* expression. (B) Same as (A) only for MCF7 breast cancer cell. (C) Same as (A) only for MDA-MB-231 breast cancer cells. Gene expression changes were measured after 8 h of menadione exposure and, to avoid confounding cell death gene expression signatures, menadione treatments for each cell line were based on a concentration that resulted in 80% cell viability after 24 h (24 h EC~80~). The 24 h EC~80~ for HepG2 was 17 μM, for MCF7 was 6.3 μM, and for MDA-MB-231 was 10 μM. Asterisks represent p-values for menadione versus vehicle for each cell type (\*\*\*p ≤ 0.001; \*\*p ≤ 0.01; \*p ≤ 0.05, Welch\'s *t*-test).Fig. 2

The work described above is not the first to demonstrate that *HIF1A* is a ROS-responsive transcript, however. Although much research effort has focused on the post-translational regulation of HIF1α levels, largely because the rapid increase in HIF1α protein stability is central to the adaptive response to hypoxia because [@bib47], [@bib48], several groups have recognized that regulation of HIF1α expression is also important [@bib45], [@bib49], [@bib50], [@bib51], [@bib52]. And, importantly, *HIF1A* expression has been linked to ROS in multiple settings: *HIF1A* mRNA is upregulated by ROS-inducing mutations in mouse lung carcinoma cells, by multiple sources of ROS in pulmonary artery smooth muscle cells, by chemotherapeutic-induced ROS, and by the ROS-inducer arsenite [@bib32], [@bib45], [@bib53], [@bib54]. Overall, in combination with this previously published work, these results demonstrate that ROS can activate *HIF1A* expression in multiple cellular contexts.

2.3. An NRF2-bound antioxidant response element (ARE) at the *HIF1A* locus {#s0025}
--------------------------------------------------------------------------

The gene expression cluster that includes *HIF1A* (Cluster 1, [Fig. 1](#f0005){ref-type="fig"}A) is significantly enriched for genes called as NRF2 targets based on ChIP-seq data. Overall, this cluster contained 53 putative NRF2 target genes ([Supplementary Table 4](#s0085){ref-type="sec"}) -- *HIF1A* is not on this list. However, the program we used to identify significant TFs for each cluster, Enrichr, is conservative in its identification of a TF\'s putative target genes because it selects for TF binding sites that are close to transcription start sites (TSS) [@bib30], [@bib55]. This conservative approach is suitable for unbiased scanning for enriched TFs across gene lists, but it is likely to miss many TF target genes because TSS-distal binding events are just as likely to regulate gene expression [@bib56]. Therefore, we used published NRF2 ChIP-seq data [@bib33], [@bib34] to manually search for NRF2 binding sites near *HIF1A*; we focused on data from human lymphoblastoid cell lines treated with sulforaphane, an NRF2 activator, because this dataset is robust and highly concordant with NRF2 ChIP-seq data from additional conditions and cell lines [@bib33], [@bib34], [@bib57]. These data revealed a strong NRF2 binding site approximately 32.5 kb upstream of the *HIF1A* TSS ([Fig. 3](#f0015){ref-type="fig"}A) (NRF2 ChIP peak coordinates: chromosome 14, 62,129,227 -- 62,129,613; GRCh37/hg19 human genome assembly). This region was also called as a strong NRF2 ChIP-seq peak in HepG2 cells, K562 leukemia cells, A549 lung cancer cells, and BEAS-2B bronchial epithelial cells (not shown). Although this NRF2 binding site is \> 30 kb from *HIF1A*, functional NRF2 targeted AREs are often distal to gene promoters [@bib58]. This binding site also falls within a topogically associated domain with *HIF1A* ([Supplementary Fig. 2A](#s0085){ref-type="sec"}), so it is structurally associated with the *HIF1A* locus and, therefore, just as likely to affect *HIF1A* expression as more proximal cis-regulatory regions [@bib59], [@bib60], [@bib61]. In addition, this NRF2 binding site falls within the most prominent enhancer region upstream of *HIF1A* based on compiled chromatin state data from 127 human tissues and cell types ([Supplementary Fig. 2B](#s0085){ref-type="sec"}) [@bib62]. Finally, this NRF2 binding event is centered on a perfect match to the ARE consensus ([Fig. 3](#f0015){ref-type="fig"}A) and, importantly, this perfect ARE sequence is strongly conserved across mammals ([Fig. 3](#f0015){ref-type="fig"}B).Fig. 3An NRF2 binding site at the *HIF1A* locus. (A) An NRF2 ChIP-seq peak and antioxidant response element (ARE) sequence at the human *HIF1A* locus. ChIP-seq data are from lymphoblastoid cell lines treated with sulforaphane [@bib33], [@bib34], [@bib57], and the same ChIP-seq peak is seen in NRF2 data from four additional human cell lines (see main text). Only protein coding genes are represented; see [Fig. S2](#s0085){ref-type="sec"} for non-coding RNAs at this locus. (B) The ARE highlighted in (A) is highly conserved. (C) NRF2-MAFG electrophoretic mobility shift assay (EMSA) using the ARE from the *NQO1* promoter as a labeled probe. Lane 1 contains the labeled *NQO1* ARE probe with no protein, lane 2 contains the *NQO1* probe with purified MAFG only, lane 3 contains the *NQO1* probe with purified NRF2 only, and lane 4 contains the *NQO1* probe with NRF2 and MAFG. Binding is only seen when both proteins are present in the reaction. Lanes 5--8: NRF2 and MAFG are present in each lane. Competition reactions included addition of excess unlabeled competitor probes containing the wild-type (WT) *HIF1A* ARE, a mutated (mut) *HIF1A* ARE, the wild-type *NQO1* ARE, or a mutated *HIF1A* ARE, as indicated.Fig. 3

Based on the ChIP-seq data, NRF2 binding at the ARE-containing HIF1A enhancer is significantly stronger in cells treated with the NRF2-inducer sulforaphane in comparison cells treated with vehicle control ([Supplementary Fig. 3A--B](#s0085){ref-type="sec"}). In addition, electrophoretic mobility shift assays (EMSAs) performed with nuclear lysates from either vehicle- or menadione-treated MCF7 cells revealed a ROS-responsive protein binding signal at the *HIF1A* ARE is nearly identical to ROS-responsive binding at the *NQO1* ARE, a well-studied NRF2 binding site ([Supplementary Fig. 3C--D](#s0085){ref-type="sec"}). These results further support the idea that NRF2 can bind ARE sequence within the ChIP-seq peak upstream of *HIF1A*, so we then used EMSAs with affinity purified proteins to determine whether NRF2, in complex with its DNA binding cofactor MAFG, can directly bind the *HIF1A* ARE. Specifically, we performed competition-based EMSAs using a labeled DNA probe based on the well-studied ARE at the *NQO1* locus -- this probe was bound by NRF2-MAFG heterodimers ([Fig. 3](#f0015){ref-type="fig"}C). As expected, an unlabeled version of the *NQO1* probe competes for binding with the labeled probe, and mutation of the *NQO1* ARE sequence eliminates competition for binding; thus, this interaction is specific and ARE-dependent. Importantly, a similar pattern was seen with the *HIF1A* ARE sequence, which also competed for binding with the labeled *NQO1* probe in an ARE-dependent manner. Thus, NRF2, in complex with its DNA binding cofactor MAFG, directly binds the *HIF1A* ARE sequence.

To determine whether the *HIF1A* ARE has *cis*-regulatory activity, we generated plasmid constructs in which this ARE-containing region drives expression of the *luciferase* reporter gene. Both wild type (*HIF1A*^WT^) and ARE mutant (*HIF1A*^Mut^) constructs were generated, and reporter assays were performed in HepG2, MCF7, and MDA-MB-231 cells, with or without menadione treatment. Reporter assays performed with TBOOH treatment were unsuccessful because all luciferase activity, even for positive controls, was eliminated by TBOOH (not shown); menadione did not have this effect, so it was our ROS inducer of choice for these assays. As seen in [Fig. 4](#f0020){ref-type="fig"}, menadione treatment led to a significant increase in *HIF1A*^WT^ reporter activity in all three cell types, and this induction was eliminated by mutation of the ARE sequence (*HIF1A*^Mut^). Interestingly, the ARE is required for both basal (non-stress) and inducible activity of this region in MCF7 and HepG2 cells, while it is only required for inducible activity in MDA-MB-231 cells. This suggests that additional, non-ARE binding TFs might also act on this DNA region to promote basal expression in MDA-MB-231 cells. Despite these cell-specific differences, the *HIF1A* ARE is clearly responsible for menadione-driven increases in the regulatory output of this DNA region. Taken together, the results described in this section indicate that this deeply conserved NRF2 binding site is a functional ARE that falls within an important *HIF1A*-associated enhancer region.Fig. 4Menadione treatment increases *HIF1A* ARE activity in multiple cell types. (A) Reporter assays in which the region surrounding the *HIF1A* ARE (*HIF1A*^WT^), or a construct in which the ARE was mutated (*HIF1A*^Mut^), were cloned upstream of a luciferase reporter gene. HepG2 cells were transfected with each plasmid and treated with either vehicle control (EtOH) or menadione for 24 h. Cells were then assessed for luciferase activity, and all values were normalized to a control reporter plasmid driven by the *LDHA* promoter region. (B) Same as (A) only for MCF7 breast cancer cell. (C) Same as (A) only for MDA-MB-231 breast cancer cells. P-values for menadione versus vehicle for each reporter construct are represented with asterisks (\*\*\*p ≤ 0.001; \*\*p ≤ 0.01; \*p ≤ 0.05, Welch\'s *t*-test).Fig. 4

2.4. A role for NRF2 in HIF1A expression {#s0030}
----------------------------------------

The above findings indicate that (1) *HIF1A* gene expression is ROS-responsive and (2) the ROS-responsive TF NRF2 can bind and transactivate an ARE upstream of *HIF1A*. Both points suggest NRF2 is a transcriptional regulator of *HIF1A*, and this is further supported by previous work implicating NRF2 in regulation of HIF1α. For example, NRF2 knockdown impairs hypoxia-mediated induction of HIF1α in both glioblastoma and colon cancer cells, and NRF2 overexpression drives HIF1α induction in multiple cancer cell lines [@bib63], [@bib64], [@bib65]. NRF2 is also required for HIF1α mRNA and protein induction during induced pluripotent stem cell reprogramming [@bib31]. And, importantly, NRF2 is required for arsenite-mediated upregulation of HIF1α in HepG2 hepatoma cells [@bib32]. To build on these data, we used genome-edited *NRF2* knockout MDA-MB-231 cells to test whether NRF2 plays a role in menadione-driven *HIF1A* induction in this cell line. Consistent with the results from [Fig. 2](#f0010){ref-type="fig"}, *HIF1A* was induced by menadione in control MDA-MB-231 cells ([Fig. 5](#f0025){ref-type="fig"}A). However, *HIF1A* was also induced by menadione in *NRF2* knockout cells, but this induction was not as robust as that of control MDA-MB-231 cells ([Fig. 5](#f0025){ref-type="fig"}A). For context, we also tested expression of *NQO1*, a well characterized NRF2 target gene [@bib66], in these conditions. Consistent with its role as a canonical NRF2 target, *NQO1* expression was largely NRF2-dependent under basal conditions and after treatment with menadione; however, it was still upregulated by menadione, suggesting additional TFs play a small role in inducible *NQO1* expression in this cell type. Thus, although much work suggests that *HIF1A* expression is regulated by NRF2, it is not overwhelmingly NRF2-dependent like *NQO1*, at least in MDA-MB-231 breast cancer cells [@bib32], [@bib63], [@bib64], [@bib65]. Instead, this experiment implies NRF2 plays a role in *HIF1A* expression, but additional TFs also regulate *HIF1A* in certain cellular contexts. Consistent with this model, ROS-mediated activation of HIF1α is regulated in part by the phosphatidylinositol 3-Kinase/AKT signaling pathway and the TF NFκB [@bib51], [@bib53], [@bib54], [@bib67], so NRF2 is just one of multiple ROS-responsive factors regulating HIF1α levels.Fig. 5Menadione-driven upregulation of *HIF1A* is reduced in *NRF2* knockout cells cells. (A) *HIF1A* expression in control MDA-MB-231 breast cancer cells and *NRF2* knockout MDA-MB231 cells treated with vehicle control (Veh.) or menadione (Men.) for 8 h. Gene expression values were measured by quantitative reverse transcription PCR and normalized relative to *ACTB* expression. (B) Same as (A), only for *NQO1* expression. P-values for menadione versus vehicle within a genotype are represented with asterisks (\*\*\*p ≤ 0.001; \*\*p ≤ 0.01; \*p ≤ 0.05, Welch\'s *t*-test) and p-values for *NRF2* knockout versus the control MDA-MB-231 within a treatment are represented with hashes (^\#\ \#\ \#^p ≤ 0.001; ^\#\ \#^p ≤ 0.01; ^\#^p ≤ 0.05, Welch\'s *t*-test).Fig. 5

Data from The Cancer Genome Atlas (TCGA) provide an additional avenue for exploring the relationship between NRF2 activity and expression of its downstream genes. The TCGA project has generated genome-wide profiling data (genotype and gene expression) for thousands of clinical tumor samples across more than 30 cancer types. This is useful because mutations that disrupt the interaction between NRF2 and its inhibitor KEAP1 are common in multiple cancer types -- these mutations, which can occur in either *NRF2* or *KEAP1*, drive constitutive NRF2 activity and provide cells with multiple oncogenic advantages [@bib68], [@bib69], [@bib70]. To test the impact of oncogenic NRF2 activity on downstream expression of *HIF1A* (and, for comparison, *NQO1*) we looked at the expression of both genes in the three cancer types where mutations in *NRF2* or *KEAP1* are most prevalent: bladder carcinoma (BLCA), lung squamous cell carcinoma (LUSC), and lung squamous cell carcinoma (LUAD) [@bib71], [@bib72], [@bib73], [@bib74]. For each cancer, we separated individual tumors into those with no mutation in *NRF2* or *KEAP1* (*NRF2*^*WT*^; *KEAP1*^*WT*^), those with a mutation in *NRF2* (*NRF2*^*mut*^), and those with a mutation in *KEAP1* (*KEAP1*^*mut*^); we then compared the expression of *HIF1A* and *NQO1* across the three tumor classes for each cancer type ([Fig. 6](#f0030){ref-type="fig"}A). *NQO1* upregulation in *NRF2*^*mut*^ tumors was significant across all three cancer types, consistent with the idea that cancer-associated *NRF2* mutations often lead to NRF2 hyperactivation; a similar, though less robust, pattern was seen for *NQO1* expression in *KEAP1*^*mut*^ tumors. The situation was more complex with *HIF1A* expression. *HIF1A* was generally unaffected in *KEAP1*^*mut*^ tumors and in LUAD tumors, but *NRF2*^*mut*^ tumors were consistently associated with higher than average *HIF1A* expression in bladder and lung carcinoma (BLCA and LUSC). Thus, whereas *NQO1* is almost always induced in tumors with presumed NRF2 hyperactivating mutations, NRF2-associated induction of *HIF1A* is limited to select cancer types (BLCA and LUSC).Fig. 6NRF2 target gene induction in tumors with high NRF2 activity. (A) Gene expression values for *NQO1* and *HIF1A* in bladder carcinoma (BLCA), lung squamous cell carcinoma (LUSC), and lung adenocarcinoma (LUAD). For each cancer, tumors with mutated *NRF2* (*NRF2*^*mut*^) or mutated *KEAP1* (*KEAP1*^*mut*^) were separated from tumors with no mutations in either gene (*NRF2*^*WT*^; *KEAP1*^*WT*^). Expression values are based on pan-cancer normalized RNA-seq data from The Cancer Genome Atlas (TCGA); each dot represents expression levels from a single tumor, and horizontal lines represent the mean expression for the cancer/genotype population. Significant changes in *NRF2*^*mut*^ or *KEAP1*^*mut*^ relative to *NRF2*^*WT*^; *KEAP1*^*WT*^ are indicated (Wilcoxon rank-sum test; \*\*\*p ≤ 0.001; \*\*p ≤ 0.01; \*p ≤ 0.05) (B) Gene expression values for *NQO1* and *HIF1A* in breast cancer (BRCA) tumors. Tumors with high inferred NRF2 activity were separated from normal tumors based on a 32 gene NRF2 expression signature (see Methods). As in (A), expression values are based on pan-cancer normalized RNA-seq data from TCGA; each dot represents expression levels from a single tumor, and horizontal lines represent the mean expression for each population. Expression in tumors with high inferred NRF2 activity was compared to expression in tumors with normal inferred NRF2 activity, and significant differences are indicated (Wilcoxon rank-sum test; \*\*\*p ≤ 0.001; \*\*p ≤ 0.01; \*p ≤ 0.05).Fig. 6

*HIF1A* expression is also important in breast cancer cells, where high HIF1α levels are associated with cancer stem cell enrichment and chemoresistance [@bib45], [@bib46]. Although oncogenic *NRF2* mutations are rare in breast cancer, NRF2 can also be indirectly hyperactivated in many cancer types [@bib75], [@bib76]. Thus, we used TCGA data to identify breast cancer (BRCA) tumors with high *inferred* NRF2 activity based on a 32 gene NRF2 expression signature (Levings et al. [@bib87]) (see Methods) [@bib77]. Consistent with our finding that *HIF1A* is ROS-responsive in breast cancer cell lines, *HIF1A* is also high in breast cancer tumors with high inferred NRF2 activity ([Fig. 6](#f0030){ref-type="fig"}B). Overall, the gene expression patterns in clinical tumor samples are consistent with the regulatory strategies implied by the *NRF2* knockout results: activation of *NQO1* by oncogenic NRF2 was consistent across all four cancer types, whereas NRF2-associated activation of *HIF1A* was dependent on cancer type, and most robust in bladder and breast cancer. Together, these results support a model in which *HIF1A* expression is the result of input from multiple TFs, and one of these TFs is NRF2.

3. Conclusion {#s0035}
=============

One of the benefits of genomics-based approaches is that they can highlight unexpected or underappreciated connections between regulatory networks. Here, we leveraged multiple sources of publicly available functional genomics data to identify a direct regulatory connection between the redox-responsive TFs NRF2 and HIF1α. We identified a robust in situ NRF2 binding event upstream of *HIF1A*. This NRF2 binding site is centered on a strongly conserved ARE that is directly bound by NRF2 in vitro and drives ROS-responsive gene expression in luciferase reporter assays. In addition, this ARE falls within the most prominent enhancer region upstream of *HIF1A* based on chromatin state data, suggesting it falls within an important *cis*-regulatory region. Additionally, we find that *HIF1A* expression is enhanced by oncogenic *NRF2* mutations in certain cancer types. In combination with previously published studies implying a role for NRF2 in *HIF1A* expression [@bib31], [@bib32], [@bib63], [@bib64], [@bib65], this work suggests NRF2 is a direct regulator of *HIF1A*.

The exact setting(s) where direct regulation of *HIF1A* transcription by NRF2 is most relevant remain subject to speculation, with both hypoxic and non-hypoxic contexts as possibilities. Hypoxia triggers a paradoxical increase in ROS, largely via the mitochondria, that is thought to inhibit PHD-mediated degradation of HIF1α and increase HIF1α activity [@bib78], [@bib79]. ROS-dependent transcriptional induction of *HIF1A*, via NRF2 and other TFs, would provide a parallel mechanism for increasing HIF1α activity during hypoxia. NRF2-mediated induction of *HIF1A* might also be important in cancer settings, where we found NRF2-associated *HIF1A* increases in bladder carcinoma, lung carcinoma, and breast cancer. NRF2 can be directly activated in cancer via mutation in *NRF2* or *KEAP1*, indirectly activated via additional oncogenic pathways, and possibly activated by ROS generated during hypoxia, which is common in solid tumors -- downstream activation of *HIF1A* could be important in any of these tumorigenic conditions. An additional cancer related link is that arsenite-mediated induction of HIF1α via NRF2 is growth promoting, and may explain part of arsenite\'s carcinogenicity [@bib32]. Further, in triple negative breast cancer cells, ROS induction by chemotherapeutic drugs leads to an increase HIF1α (mRNA and protein), which then promotes cancer stem cell formation and chemoresistance [@bib45]. In this context, it is also worth mentioning that NRF2 and HIF1α both directly regulate the antioxidant genes *GCLM* and *SLC7A11*, which have also been linked to chemoresistance and cancer stem cell formation [@bib45], [@bib46], [@bib80], [@bib81]. Overall, there are several links between ROS, NRF2 activity, and HIF1α levels in cancer, and the connections between NRF2 and HIF1α likely extend to shared target genes regulated by both TFs.

Beyond hypoxia and cancer, a third setting where NRF2-driven induction of *HIF1A* could be important is during induced pluripotent stem cell (iPSC) formation [@bib31]. Early iPSC reprogramming is associated with a burst of oxidative phosphorylation, elevated ROS, and increased NRF2 activity. Shortly thereafter, HIF1α mRNA and protein levels increase in an NRF2-dependent manner, and HIF1α drives a shift toward glycolytic metabolism that is required for efficient iPSC reprogramming. The exact mechanism by which NRF2 upregulates HIF1α during iPSC generation is yet unknown, but our results suggest that direct transcriptional regulation is a likely mechanism.

Regulation of HIF1α levels by NRF2 also extends beyond direct control of its transcription; the protein products of two prominent NRF2 target genes, *NQO1* and *TXN* (also known as *TRX1*), also interact with HIF1α and increase its stability [@bib82], [@bib83], [@bib84]. NRF2 activation, therefore, has the potential to increase both *HIF1A* expression and HIF1α stability. Ultimately, additional work will be required to find the settings where NRF2\'s induction of *HIF1A* transcription is most critical. Regardless, the fact that HIF1α is both part of the NRF2 regulatory network (directly targeted by NRF2) and stabilized by members of the NRF2 regulatory network (TXN, NQO1), suggests that the connection between these two redox-responsive TFs is an important one.

4. Materials and methods {#s0040}
========================

4.1. Chemicals and materials {#s0045}
----------------------------

FuGENE HD transfection reagent was purchased from Promega (Madison, WI). Menadione was purchased from MP Biomedicals (Solon, OH), and Luperox (tert-butyl hydroperoxide solution; TBOOH) was purchased from Sigma-Aldrich Chemical Company (St. Louis, MO). Stock solutions of all test compounds were prepared in 100% Ethanol. MISSION LightSwitch Luciferase Assay Reagent was purchased from Sigma-Aldrich. All oligonucleotides used for gel mobility shift assays and cloning were purchased from Integrated DNA Technologies (Coralville, IA).

4.2. Cells lines and cell culture {#s0050}
---------------------------------

The human hepatocellular carcinoma HepG2 cells and the human breast cancer MCF7 and MDA-MB-231 cells were purchased from the American Type Culture Collection (ATCC). Genome edited NFE2L2/NRF2 knockout MDA-MB-231 cells were generated by GenScript (Piscataway, NJ) using GenCRISPR gene editing technology. Targeted disruption of NRF2\'s final exon resulted in a biallelic 1b deletion upstream of the basic leucine zipper domain, which was confirmed by Sanger sequencing; the deleted base coordinate is chromosome 2, position 178095987 (GRCh37/hg19 genome assembly). HepG2 cells were grown and maintained in EMEM culture media (ATCC), supplemented with 10% fetal bovine serum purchased from Atlanta Biologicals (Norcross, GA), and 1% (v/v) penicillin/streptomycin purchased from Invitrogen-Life technologies (Carlsbad, CA). MCF7 and MDA-MB-231 cells were grown and maintained in IMEM culture media (Gibco), supplemented with 5% fetal bovine serum purchased from (Atlanta Biologicals), 1% (v/v) penicillin/streptomycin (Invitrogen-Life technologies), 11.25 nM bovine insulin from Sigma-Aldrich, and 2.5 μg/L plasomicin prophylactic (InvivoGen, San Diego, CA). All cell lines were maintained at 37 °C in humidified 5% CO~2~ air.

4.3. Microarray gene expression profiling and ChIP-seq data {#s0055}
-----------------------------------------------------------

Gene expression microarray data as described by Deferme et al. (GEO series accession number [GSE39291](ncbi-geo:GSE39291){#ir0005}). To calculate log~2~ fold change values, average expression values from the 0.5, 1, 2, 4, 8, and 24 h time points for each treatment were compared to the average expression value from the corresponding control sample at each time point. Genes with \|log~2~ fold change\| \> 0.58 in at least one of the twelve comparisons were then grouped into clusters of similar expression pattern using the hierarchical clustering tool within TM4\'s MeV Stand-Alone Client (<http://mev.tm4.org>). Individual clusters were then analyzed using Enrichr [@bib30] to identify putative transcription factors regulating genes within the cluster; we called a TF (from the 'ENCODE and ChEA Consensus TFs from ChIP-X' category) as enriched for binding genes in a given cluster if its adjusted enrichment p-value was \< 0.001 (Fisher\'s exact test) and combined Enrichr score was \> 10 (see [Supplementary Table 1](#s0085){ref-type="sec"}). NRF2 ChIP-seq data are from lymphoblastoid cell lines treated with sulforaphane, as described previously -- the sequencing data for this ChIP-seq experiment can be accessed under GEO Accession Number [GSE37589](ncbi-geo:GSE37589){#ir0015} [@bib33], [@bib34], [@bib57].

4.4. Electrophoretic mobility shift assays {#s0060}
------------------------------------------

NRF2 was purified from BL21 bacteria transfected with pPROHEX-HC-Flag3-NRF2 as His-tagged fusions using Ni-agarose beads as described previously [@bib85], [@bib86]. Purified his-tagged NRF2 (28.1 nM), MAFG (28.1 nM), and IRDye-700 labeled double stranded DNA were incubated for 30 min at room temperature with poly(dI-dC) in the binding buffer (20 mM HEPES, 4 mM MgCl~2~, 100 μg/ml BSA, 4% glycerol, 20 mM KCl, 5 mM DTT, and 1 mM EDTA). Orange loading dye (LI-COR, Lincoln, NE) was added and samples were electrophoresed through a native acrylamide gel in 1X TBE. Gels were imaged using the Odyssey® infrared imaging system (LI-COR, Lincoln, NE). The EMSA in [Supplementary Fig. 3](#s0085){ref-type="sec"}A was performed with MCF7 nuclear lysates isolated using the Active Motif Nuclear Extract kit (Carlsbad, CA). The double stranded oligonucleotides containing the following sequences were used for the electrophoretic mobility shift assay (EMSA): IRDye-700 5'-AATCCGCAGTCACA**[GTGACTCAGCA]{.ul}**GAATCTGAGCCTAG-3' (*NQO1* ARE, Labeled), 5\'-AATCCGCAGTCACA**[GTGACTCAGCA]{.ul}**GAATCTGAGCCTAG-3'(*NQO1* cold competitor), 5\'-AATCCGCAGTCACA**[GACTCCTACGA]{.ul}**GAATCTGAGCCTAG-3' (Mutant *NQO1* cold competitor), 5'-TCAGTGACCCATCT[T]{.ul}**[GCTGAGTCA]{.ul}**[T]{.ul}GCTAAACCTGTTGA-3' (*HIF1A* cold competitor; Labeled version used in [Supplementary Fig. 3](#s0085){ref-type="sec"}), 5'-TCAGTGACCCATCT[T]{.ul}**[GCTGAAAAA]{.ul}**[T]{.ul}GCTAAACCTGTTGA-3' (Mutant *HIF1A* cold competitor).

4.5. Reporter assays {#s0065}
--------------------

All reporter plasmids are based on the Switchgear Genomics (Carlsbad, CA) LightSwitch optimized luciferase reporter vector system. The *LDHA* (*lactate dehydrogenase A*) control reporter construct was purchased directly from Switchgear Genomics (Product ID: S721613). To generate the *HIF1A* ARE constructs (both wild type and ARE mutant), we annealed oligonucleotides containing the ARE enhancer sequences into the pLightSwitch-LR Reporter Vector (SwitchGear Genomics, catalog number 32024). The pLightSwitch vector was cut with BglII and MluI purchased from New England Biolabs (Ipswich, MA), and the annealed oligonucleotides contained overhanging sequences compatible with a BglII and MluI insertion site. Annealing the following two oligonucleotides generated the *HIF1A*^WT^ insert: 5'-*CGCG*GGTGTTCAGTGACCCATCTT**GCTGAGTCA**TGCTAAACCTGTTGAGCATG-3' and 5'- *GATC*CATGCTCAACAGGTTTAGCA**TGACTCAGC**AAGATGGGTCACTGAACACC-3' (ARE region is bold, and overhang cloning sequences are italicized). An equivalent oligonucleotide pair generated the *HIF1A*^Mut^ insert: 5'-*CGCG*GGTGTTCAGTGACCCATCTT**GCTGA[AAA]{.ul}A**TGCTAAACCTGTTGAGCATG-3' and 5'-*GATC*CATGCTCAACAGGTTTAGCA**T[TTT]{.ul}TCAGC**AAGATGGGTCACTGAACACC-3' (ARE region is bold, mutated sequences within the ARE region are underlined, and overhang cloning sequences are italicized). For reporter assays, cells were seeded and transfected in Opti-MEM (Invitrogen) supplemented with 10% FBS. 96 well plates were seeded with 15,000 cells/well and simultaneously transfected using the SwitchGear Genomic High-throughput transfection protocol. Each transfection included 0.15 μl of FuGENE HD transfection reagent and approximately 50 ng/well of reporter plasmid. Each construct was transfected in at least four replicates, and plates were incubated at 37 °C. The transfected cells were treated with 10 μM menadione 24 h post transfection. Then the cells were incubated for an additional 24 h at 37 °C before being frozen at −80 °C. Plates were removed from the freezer and allowed to reach room temperature. 100 μl of MISSION LightSwitch Luciferase Assay Reagent was added to each well, and plates were incubated at room temperature for 30 min and read on a SpectraMax M3 (Molecular Devices, Sunnyvale, CA) according to the manufacturer\'s instructions. Statistical analysis (Welch\'s *t*-test) was performed using Graphpad Prism (La Jolla, CA).

4.6. Reverse transcription and quantitative PCR {#s0070}
-----------------------------------------------

Cells were seeded at 125,000 cells/ml in a 6-well plate and grown at 37 °C for 24 h, then treated with either vehicle (0.1% ETOH), or the experimentally determined EC~80~ (the concentration required to maintain a live cell population of 80%) of the two ROS inducers- TBOOH or menadione. The EC~80~ for TBOOH and menadione was determined individually for each cell type using the CellTiter-Fluor kit from Promega (Madison, WI). The EC~80~ concentrations used to induce ROS in the cell lines were as follows: HEPG2, 300 μM TBOOH, 17 μM menadione; MCF7, 80 μM TBOOH, 6.3 μM menadione; MDA-MB-231, 100 μM TBOOH, 10 μM menadione. Each cell type was treated in a minimum of three replicates, and plates were incubated at 37 °C. EtOH concentrations remained at a constant concentration of 0.1% across all treatment groups. Following drug treatment for 8 h, total RNA was isolated using the Qiagen RNeasy kit. Reverse transcriptase PCR was performed according to manufacturer\'s instructions (Omniscript RT kit, Qiagen) using 1.0 μg of total RNA to generate cDNA. Primers for *HIF1A* (FAM-hydrolysis probe, Hs.PT.58.534274), *SQSTM1* (FAM-hydrolysis probe, Hs.PT.58.39829257), *NQO1* (FAM-hydrolysis probe, Hs.PT.58.2697277), and *ACTB* (HEX-hydrolysis probe, Hs.PT.39a.22214847) were purchased from the predesigned PrimeTime qPCR Assays (Integrated DNA Technologies). RT-PCR reactions were performed using a LightCycler 480 Multiwell Plate 96 containing 5 μM of each primer set, 1× LightCycler 480 Probes Master (Roche Diagnostics, Bazel, Switzerland), and 2 μl of cDNA template, in a final reaction volume of 10 μl. The RT-PCR was performed using the following cycle parameters: initial enzyme activation at 95 °C for 10 min; followed by 45 cycles of 95 °C for 10 s, 60 °C for 20 s, and 65 °C for 30 s. Following the amplification phase, a cooling step was performed at 40 °C for 10 s (ramp rate of 1.5 °C/s). Acquisition of the fluorescence signal was performed using the Dual Hydrolysis Probe setting for FAM (465--510 nm) and HEX/Yellow555 (533--580) dyes following the 65 °C extension phase of each cycle. Relative expression of selected genes was evaluated using qPCR by calculating the ratio of the specific gene to *β-Actin* (*ACTB*). Statistical analysis (Welch\'s *t*-test) was performed using Graphpad Prism (La Jolla, CA).

4.7. Analysis of TCGA gene expression data {#s0075}
------------------------------------------

To assess if *HIF1A* expression is induced in cancers with NRF2 hyperactivation, we used data from The Cancer Genome Atlas (TCGA). First, using XenaPython we downloaded two sets of data for all samples from the cancer types BLCA, HNSC, LUSC and UCEC in TCGA: 1) pan-cancer normalized gene expression values from the UCSC TOIL recompute for *NQO1 and HIF1A*, and 2) all non-silent mutations in *NFE2L2* for these samples. We then used *R* to generate dotplots depicting the spread of the gene expression values, with means for the two genes listed above in *NRF2*^*WT*^ and *NRF2*^*mut*^ tumors from each cancer. P-values were calculated using the non-parametric Mann-Whitney-Wilcox test in *R*. N\'s for each group are as follows (each gene has the same N for each cancer/NRF2 status combination): BLCA -- *NRF2^WT^/KEAP1*^*WT*^ = 359, *NRF2*^*mut*^ = 23, *KEAP1^mu^*^t^ = 8; LUSC -- *NRF2^WT^/KEAP1*^*WT*^ = 128, *NRF2*^*mut*^ = 27, *KEAP1^mut^* = 22; LUAD -- *NRF2^WT^/KEAP1*^*WT*^ = 385, *NRF2*^*mut*^ = 12, *KEAP1^mut^* = 88.

For analysis of BRCA, where NRF2 mutations are rare, we used a 32 gene NRF2 signature to infer NRF2 activity in individual tumors. The 32 gene signature is based on direct NRF2 target genes that are reliably upregulated by oncogenic NRF2 (Levings et al. [@bib87]) and consists of the following genes: *ABCB6*, *ABCC3, AKR1C3, ANXA10, ASF1A, DNAJB4, EPHX1, FECH, FTH1, GCLC, GCLM, GSR, GSTM3, KEAP1, MAFG, ME1, NAMPT, NECAB2, NQO1, PANX2, PIR, PRDX1, SLC3A2, SLC7A11, SRXN1, TKT, TLK1, TMTC3, TRIM16L, TXN, TXNRD1, ZNF746*. We calculated a mean expression value across all 32 NRF cancer signature genes for each BRCA sample, then computed the value for the 95th percentile of this mean expression across all samples. Any sample with a mean expression above this 95th percentile was assigned to the high NRF2 group (N = 49), and any at or below this value was assigned normal NRF2 (N = 928).

Appendix A. Supplementary material {#s0085}
==================================
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